Showing results (91-100 of 830) with videos related to
Sort By:
Pageof 83
The New England Journal of Medicine|December 14, 2016
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary DiseaseAmit V Khera, Connor A Emdin, Isabel Drake, et al.Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Race, Socioeconomic Deprivation, and Hospitalization for COVID-19 in English participants of a National BiobankAniruddh Pradip Patel, Manish D Paranjpe, Nina P Kathiresan, et al.International Journal for Equity in Health|July 8, 2020
Race, socioeconomic deprivation, and hospitalization for COVID-19 in English participants of a national biobankAniruddh P Patel, Manish D Paranjpe, Nina P Kathiresan, et al.Diabetes|April 16, 2017
Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart DiseaseConnor A Emdin, Derek Klarin, Pradeep Natarajan, et al.Circulation Research|September 24, 2005
Apolipoprotein E suppresses the type I inflammatory response in vivoKamilah Ali, Melissa Middleton, Ellen Puré, et al.Journal of the American College of Cardiology|June 7, 2008
Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approachesEmil M deGoma, Rolando L deGoma, Daniel J RaderScience Translational Medicine|July 24, 2010
Could exercise metabolomics pave the way for gymnomimetics?Megan F Burke, Richard L Dunbar, Daniel J RaderCirculation Research|June 7, 2014
Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndromeRobert S Rosenson, H Bryan Brewer, Daniel J RaderEuropean Heart Journal. Cardiovascular Pharmacotherapy|September 22, 2022
RNA-targeted therapeutics in cardiovascular disease: the time is nowKonstantin A Krychtiuk, Daniel J Rader, Christopher B GrangerBiochemical Society Transactions|October 31, 2015
Tribbles-1: a novel regulator of hepatic lipid metabolism in humansRobert C Bauer, Batuhan O Yenilmez, Daniel J RaderPageof 83